# US 2013/0280697 A1 · HEV Assay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280697 A1
- Document ID: US20130280697A1
- Status: Published application
- Kind: A1
- Application number: 13/864,439
- Filed: 2013-04-17
- Published: 2013-10-24
- Earliest claimed: 2012-04-18
- Assignees: Roche Molecular Systems, Inc.
- Applicants: Roche Molecular Systems, Inc.
- Inventors: Hermann Leying; Thomas W. Myers; Nicolas Newton; Eberhard Russmann; Joseph San Filippo; Nancy Schoenbrunner; Heike Wilts; Xiaoning Wu; Karen K. Y. Young; Dirk Zimmermann
- Web page: https://patentgrep.com/patent/US20130280697A1

## CPC

- C12Q 1/707: {non-A, non-B Hepatitis, excluding hepatitis D}
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method of simultaneously amplifying genotypes 1, 2, 3 and/or 4 of HEV is disclosed comprising amplifying the genotypes 1, 2, 3 and/or 4 of HEV with one single none-degenerate forward primer partially overlapping the 5′UTR region of HEV and at least one reverse primer. Also disclosed are related methods comprising a probe, and kits for the detection of genotypes 1, 2, 3 and/or 4 of HEV.

## Claims

### Claim 1

A method for simultaneously amplifying genotypes 1, 2, 3 and/or 4 of HEV if present in a biological sample, comprising the steps of:
(a) isolating nucleic acids present in the biological sample;
(b) amplifying the nucleic acids isolated in step (a) using one non-degenerate forward primer and at least one non-degenerate reverse primer, wherein the forward and reverse primers are capable of simultaneously amplifying genotypes 1, 2, 3, and/or 4 of HEV.

### Claim 2 (depends on 1)

The method of claim 1, wherein the forward primer comprises a sequence selected from SEQ ID NOS: 1-6 and the at least one reverse primer comprises a sequence selected from SEQ ID NOS: 7-14.

### Claim 3 (depends on 1)

The method of claim 1, wherein the forward primer comprises SEQ ID NO: 6 and the at least one reverse primer comprises a sequence selected from SEQ ID NOS: 7-14.

### Claim 4 (depends on 1)

The method of claim 1, further comprising two non-generate reverse primers, wherein the forward primer is SEQ ID NO: 6, and the reverse primers are SEQ ID NO: 13 and SEQ ID NO: 14.

### Claim 5 (depends on 1)

The method of claim 1, wherein the nucleic acids are isolated by binding to a solid phase.

### Claim 6 (depends on 1)

The method of claim 1, further comprising the step of:
(c) detecting amplified nucleic acid obtained in step (b) as an indication of the presence of at least one of genotypes 1, 2, 3 and/or 4 of HEV in the biological sample.

### Claim 7 (depends on 6)

The method of claim 6, further comprising a probe under conditions sufficient for binding the probe to the amplified nucleic acids.

### Claim 8 (depends on 7)

The method of claim 7, wherein the probe comprises at least 20 contiguous nucleotides of SEQ ID NOS: 15-19 or 25, or a complementary sequence thereof.

### Claim 9 (depends on 7)

The method of claim 7, wherein the probe comprises at least 22 to 35 contiguous nucleotides of SEQ ID NOS: 15-19 or 25, or a complementary sequence thereof.

### Claim 10 (depends on 7)

The method of claim 7, wherein the probe consists of a sequence selected from SEQ ID NOS: 15-19 or 25, or a complementary sequence thereof.

### Claim 11 (depends on 7)

The method of claim 7, wherein the probe consists of a sequence selected from SEQ ID NO: 15-18 or 25.

### Claim 12 (depends on 7)

The method of claim 7, wherein the probe comprises a fluorophore and a quencher.

### Claim 13 (depends on 12)

The method of claim 12, wherein the fluorophore is coupled to the 5′ end of the probe, and the spacing between the fluorophore and the quencher comprises at least 9 nucleotides.

### Claim 14

A kit for amplifying genotypes 1, 2, 3 and/or 4 of HEV if present in a biological sample, comprising:
(a) a template depended DNA polymerase, nucleotides, and
(b) one non-degenerate forward primer and at least one non-degenerate reverse primer, wherein the forward and reverse primers are capable of simultaneously amplifying genotypes 1, 2, 3, and/or 4 of HEV.

### Claim 15 (depends on 14)

The kit of claim 14, wherein the forward primer comprises a sequence selected from SEQ ID NOS: 1-6 and the at least one reverse primer comprises a sequence selected from SEQ ID NOS: 7-14.

### Claim 16 (depends on 14)

The kit of claim 14, wherein the forward primer is SEQ ID NO: 6 and the at least one reverse primer comprises a sequence selected from SEQ ID NOS: 7-14.

### Claim 17 (depends on 15)

The kit of claim 15, further comprising a probe, wherein the probe comprises at least 22 to 35 contiguous nucleotides of SEQ ID NOS: 15-19 or 25, or a complementary sequence thereof.
